- Sanofi India‘s net income for Q1 2025 was 1.2 billion rupees, marking a 12% decline compared to the previous year.
- Revenue for the same period was 5.36 billion rupees, showing a 4.9% increase year-on-year but slightly underestimating the analysts’ forecast of 5.45 billion rupees.
- Other income decreased by 5.7% from the prior year, totaling 33 million rupees.
- Total costs were reduced to 3.74 billion rupees, a decrease of 2.3% compared to the previous year.
- Sanofi India plans to continue focusing on enhancing operating efficiencies to improve profitability.
- The improved operating profit in the previous quarter was attributed to successful expense management and operational efficiencies.
- Analyst ratings include 3 buy recommendations, no hold recommendations, and 1 sell recommendation.
A look at Sanofi India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi India‘s overall outlook, as indicated by the Smartkarma Smart Scores, shows a promising future ahead. With a strong emphasis on dividends (score of 5), the company is committed to rewarding its shareholders. Additionally, its high resilience score of 5 reflects the company’s ability to withstand economic challenges and uncertainties, providing a sense of stability for investors.
While the growth and value scores are moderate at 2, Sanofi India‘s momentum score of 4 suggests a positive trend in the company’s performance. With a diverse portfolio spanning prescription medicines, vaccines, biological products, generics, consumer healthcare, and animal healthcare in various markets, Sanofi India is well-positioned for long-term success in the pharmaceutical and chemical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
